Nightstar Therapeutics’ (NITE) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of Nightstar Therapeutics (NASDAQ:NITE) in a research note published on Thursday morning. The firm currently has a $31.00 price target on the stock. Wedbush also issued estimates for Nightstar Therapeutics’ FY2022 earnings at $0.83 EPS.

A number of other equities analysts have also recently issued reports on NITE. Mizuho restated a buy rating and issued a $20.00 price objective on shares of Nightstar Therapeutics in a research note on Thursday. Chardan Capital began coverage on shares of Nightstar Therapeutics in a report on Wednesday, January 3rd. They issued a buy rating and a $40.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $28.50.

How to Become a New Pot Stock Millionaire

Shares of NITE stock opened at $11.70 on Thursday. Nightstar Therapeutics has a 52-week low of $10.01 and a 52-week high of $24.93. The firm has a market capitalization of $328.77 and a PE ratio of -7.18.

Several institutional investors and hedge funds have recently bought and sold shares of NITE. Citadel Advisors LLC bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth about $240,000. Nationwide Fund Advisors bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth about $1,196,000. Essex Investment Management Co. LLC bought a new stake in shares of Nightstar Therapeutics in the 4th quarter worth about $1,771,000. Alyeska Investment Group L.P. bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth about $1,920,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of Nightstar Therapeutics in the 3rd quarter worth about $5,761,000. 29.06% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Nightstar Therapeutics’ (NITE) Outperform Rating Reaffirmed at Wedbush” was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3341248/nightstar-therapeutics-nite-outperform-rating-reaffirmed-at-wedbush.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bryn Mawr Bank  Issues  Earnings Results
Bryn Mawr Bank Issues Earnings Results
MRC Global  Upgraded to Hold by ValuEngine
MRC Global Upgraded to Hold by ValuEngine
Arcadia Biosciences  Downgraded to Sell at ValuEngine
Arcadia Biosciences Downgraded to Sell at ValuEngine
Torchmark  Upgraded by ValuEngine to “Buy”
Torchmark Upgraded by ValuEngine to “Buy”
Xilinx  Lowered to Hold at ValuEngine
Xilinx Lowered to Hold at ValuEngine
DROXNE  Reaches Market Capitalization of $548,772.00
DROXNE Reaches Market Capitalization of $548,772.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.